Short Interest in Tharimmune, Inc. (NASDAQ:THAR) Decreases By 16.8%

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 30,200 shares, a decline of 16.8% from the February 28th total of 36,300 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 64,800 shares, the days-to-cover ratio is presently 0.5 days.

Hedge Funds Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Virtu Financial LLC purchased a new position in Tharimmune, Inc. (NASDAQ:THAR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned 1.11% of Tharimmune at the end of the most recent quarter. Institutional investors own 1.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on THAR. Rodman & Renshaw assumed coverage on Tharimmune in a research report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective for the company. RODMAN&RENSHAW upgraded Tharimmune to a “strong-buy” rating in a report on Friday, December 6th.

Tharimmune Trading Up 10.2 %

NASDAQ:THAR traded up $0.13 during trading hours on Wednesday, reaching $1.41. The company had a trading volume of 9,837 shares, compared to its average volume of 356,196. The firm’s 50 day moving average price is $1.69 and its 200-day moving average price is $2.07. The firm has a market cap of $2.73 million, a price-to-earnings ratio of -0.14 and a beta of 1.28. Tharimmune has a 52 week low of $1.20 and a 52 week high of $7.46.

Tharimmune (NASDAQ:THAR) last posted its earnings results on Tuesday, March 25th. The company reported ($2.02) earnings per share for the quarter.

About Tharimmune

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).